Prescription drugs, cosmetics, food supplements, and over-the-counter medicines sold in Indonesia will be required to bear state of the art identification systems under regulations being finalized by the country’s regulatory authority, the National Agency of Drug and Food Control (BADAN POM).
By 2025, pharmaceutical companies will be required to mark all prescription drug products with 2D codes that ensure they can be tracked and traced. The regulations, which begin to be phased into effect in 2023, also require drug packaging to bear an authentication barcode.
The new identification requirements have been in the works for several years, and are intended to improve the safety and quality of drugs marketed in Indonesia.
Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.
Source used in the article: https://www.optelgroup.com/en/blog/learn-about-indonesias-pharma-serialisation-and-traceability-regulation/